Dynavax Technologies Corp
NASDAQ:DVAX
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
10.05
14.98
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Dynavax Technologies Corp
Gross Margin
Dynavax Technologies Corp
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | US |
| Market Cap | 1.7B USD |
| Gross Margin |
83%
|
| Country | FR |
| Market Cap | 6T USD |
| Gross Margin |
0%
|
| Country | US |
| Market Cap | 320.1B USD |
| Gross Margin |
67%
|
| Country | US |
| Market Cap | 147.4B USD |
| Gross Margin |
60%
|
| Country | US |
| Market Cap | 119.4B USD |
| Gross Margin |
86%
|
| Country | US |
| Market Cap | 113.8B USD |
| Gross Margin |
78%
|
| Country | US |
| Market Cap | 94.1B EUR |
| Gross Margin |
76%
|
| Country | AU |
| Market Cap | 135.4B AUD |
| Gross Margin |
52%
|
| Country | US |
| Market Cap | 82.6B USD |
| Gross Margin |
87%
|
| Country | US |
| Market Cap | 39.3B EUR |
| Gross Margin |
75%
|
| Country | NL |
| Market Cap | 34.3B EUR |
| Gross Margin |
89%
|
Dynavax Technologies Corp
Glance View
Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. The company is headquartered in Emeryville, California and currently employs 311 full-time employees. The company went IPO on 2004-02-19. The firm's products include HEPLISAV-B and CpG 1018. The HEPLISAV-B is indicated for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose hepatitis B vaccine for adults. HEPLISAV-B is a sterile solution for injection presented in 0.5 mL single-dose prefilled syringes. The firm also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. The firm is also engaged in developing CpG 1018 as a vaccine adjuvant through research collaborations and partnerships. HEPLISAV-B combines 1018, a toll-like receptor (TLR9) agonist adjuvant, and recombinant hepatitis B surface antigen (rHBsAg). The company is primarily focused on adjuvanted vaccines for coronavirus disease (COVID-19), plague, Tdap, seasonal influenza, universal influenza, and shingles.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Dynavax Technologies Corp's most recent financial statements, the company has Gross Margin of 82.9%.
You don't have any saved screeners yet
